OptiBiotix Health PLC SlimBiome Medical manufacturing agreement (8053I)
November 29 2018 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 8053I
OptiBiotix Health PLC
29 November 2018
29 November 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
SlimBiome Medical Exclusive Manufacturing Agreement
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it has agreed to grant an exclusive
license agreement to Nutrilinea S.R.L. ("Nutrilinea") for the
production, packaging, and supply of SlimBiome Medical in Europe
with the aim of maximizing the financial return for both parties.
The agreement secures manufacturing for OptiBiotix's award winning
SlimBiome(R) weight management product recently granted medical
device status and CE mark (RNS: November 27(th) 2018). Nutrilinea
will formulate and package SlimBiome(R) Medical in boxes of 30
single sachet doses for sale to its own European partners and
OptiBiotix's growing list of existing and potential international
partners.
Nutrilinea has over 15 years' experience in the design and
development of customised formulations and presentations (capsules,
tablets, sachets) for the supplement and pharmaceutical industry.
Nutrilinea has established an international reputation for
providing innovative product formulations and presentations and is
one of Europe's fastest growing providers of food supplements with
year on year growth of 30% over the last 5 years and revenues of
EUR70m. Nutrilinea has become a valued partner of OptiBiotix and
has been instrumental in the development of the Company's own brand
CholBiome(R) and the rapid sales growth of OptiBitiox's LP-LDL
products.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce this exclusive license agreement with Nutrilinea for the
manufacture and supply of SlimBiome(R) Medical as a clinically
proven solution to support weight loss. We chose Nutrilinea due to
their industry reputation, extensive European network and expertise
in manufacture of high value food and medical products for Europe
and the USA. We believe partners like Nutrilinea provide the best
opportunity of building SlimBiome Medical into a global brand. We
see CE marking and medical device registration as an exciting
extension of SlimBiome(R) from food products into high value
medical products in consumer healthcare and pharmaceutical markets
which we hope will contribute substantive revenues to OptiBiotix's
growth in the months and years ahead."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty five international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGREASFPAEKPFFF
(END) Dow Jones Newswires
November 29, 2018 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024